Place de l’irathérapie dans le traitement de l’hyperthyroïdie (notice n° 398675)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04096cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250119062347.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ben Souda, Meryem |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Place de l’irathérapie dans le traitement de l’hyperthyroïdie |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 30 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Hyperthyroidism is a frequent reason for consultation in endocrinology. His treatment is based on three therapeutic options: medical by synthetic ant thyroid, surgical and iodine 131 therapy. The choice between different therapeutic options is based on a bundle of arguments. The purpose of this work is to evaluate the contribution of iodine 131 in the treatment of hyperthyroidism. For this, we conducted a retrospective study, involving 126 cases of hyperthyroidism followed in the nuclear medicine department of the CHU Hassan II hospital in Fes. The average age of our patients was 52.7 years (21-85). The sex-ratio was one man for every 8 women. Iodine 131 was administered to all our patients at an average dose of 13.94 mci (8-25). Treatment efficacy was defined as switching to hypothyroidism or euthyroidism. The final results showed that 48.4% of the cases (n = 61) had gone into euthyroidism, 48.4% (n = 61) of hypothyroidism, while 3.2 % (n = 4) remained in hyperthyroidism. The tolerance of Iodine 131 treatment was excellent, no complication was observed. Iodine 131 therapy is a simple, minimally invasive treatment. In addition, it has a moderate cost compared to surgery and drug treatments followed for several years. The socioeconomic context of the Moroccan patients suggests the widening of the fields of use of the iodine 131 in hyperthyroidism. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’hyperthyroïdie est un motif fréquent de consultation en endocrinologie. Son traitement repose sur trois options thérapeutiques : médical par antithyroïdiens de synthèse, chirurgical et l’irathérapie à l’iode 131. Le choix entre ces différentes options thérapeutiques repose sur un faisceau d’arguments. Le but de ce travail est d’évaluer la contribution de l’iode 131 dans le traitement de l’hyperthyroïdie. Pour cela, nous avons mené une étude rétrospective, incluant 126 cas d’hyperthyroïdie suivis dans le service de médecine nucléaire du CHU Hassan II de Fès et ayant reçu une irathérapie sur une période de cinq ans. L’âge moyen de nos patients était de 52,7 ans (21-85). Le sex-ratio était d’un homme pour huit femmes. L’iode 131 a été administré à tous nos malades à une dose moyenne de 13,94 mci (8-25). L’efficacité de traitement a été définie par le passage en hypothyroïdie ou en euthyroïdie. Les résultats finaux avaient montré que 48,4 % des cas (n = 61) étaient passés en eutyhroïdie, 48,4 % (n = 61 cas) en hypothyroïdie, alors que 3,2 % (n = 4) étaient restés en hyperthyroïdie. La tolérance du traitement par l’iode 131 était excellente, aucune complication n’a été observée. La thérapie par iode 131 constitue un traitement simple et peu invasif. Sa tolérance est bonne. Il a par ailleurs un coût modéré par rapport à la chirurgie et les traitements médicamenteux suivis pendant plusieurs années. Le contexte socio-économique des patients marocains suggère l’élargissement des champs d’utilisation de l’iode 131 en matière d’hyperthyroïdie. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | rapport de cas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | iode 131 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | efficacité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | irathérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hyperthyroïdie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hyperthyroidism |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | case report |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | radioiodine therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | iodine 131 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | efficiency |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Marhari, Halima |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fokoue, Fabrice |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Salhi, Houda |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | El Ouahabi, Hanan |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Alaoui, Nadia Ismaili |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Cahiers Santé Médecine Thérapeutique | 31 | 2 | 2022-03-01 | p. 144-149 | 2780-8858 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2022-2-page-144?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-cahiers-sante-medecine-therapeutique-2022-2-page-144?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux